The anticancer effects of ivaltinostat (Table 3), an intravenous hydroxamate-based pan-HDAC inhibitor previously referred to as CG200745, have been reported in various solid tumors like prostate cancer, cholangiocarcinoma, and pancreatic cancer [143], and it is said to induce cell death by modulating acetylation of p53, a tumor suppressor. The gene discussed is HDAC9; the disease is familial pancreatic carcinoma.